Isolation and characterization of bacteriophages against antibiotic-resistance Pseudomonas aeruginosa
Abstract
Background and Objectives: As an important opportunistic pathogen, Pseudomonas aeruginosa is associated with severe infections and increasing antimicrobial resistance. The growing prevalence of multidrug-resistant (MDR) strains has renewed interest in bacteriophages as alternative antibacterial agents. The present study sought to isolate and characterize lytic bacteriophages from hospital wastewater active against antibiotic-resistant clinical P. aeruginosa isolates.
Materials and Methods: Fifty clinical isolates of P. aeruginosa were obtained and tested for antimicrobial susceptibility. Bacteriophages were isolated from hospital wastewater by enrichment and spot assay screening, followed by plaque purification and titration using the double-layer agar method. The host range of purified phages was evaluated against the clinical isolates. Adsorption assays and one-step growth experiments were performed to determine adsorption efficiency, latent period, and burst size. Transmission electron microscopy (TEM) was used to examine phage morphology.
Results: A considerable proportion of the clinical isolates showed multidrug-resistant phenotypes, and a considerable number were also classified as extensively drug-resistant. Four lytic bacteriophages, designated HSP1-HSP4, were successfully isolated and purified. All produced clear plaques and reached high titers. Host range analysis showed variable lytic spectra, with HSP1 exhibiting the broadest activity and showing lytic activity against 70% of the tested isolates, followed by HSP2 (58%), HSP3 (48%), and HSP4 (40%). Adsorption analysis indicated that over 80% of phage particles attached to their host cells within 10 minutes, while HSP1 exhibited the highest adsorption efficiency at 93.6%. A short latent period of approximately 20 minutes was observed for all four phages, and burst sizes ranged from 56 to 65 PFU/cell. Transmission electron microscopy revealed isometric heads and contractile tails, morphologically consistent with tailed phages of the class Caudoviricetes.
Conclusion: Hospital wastewater can serve as a practical source for the isolation of lytic bacteriophages active against antibiotic-resistant P. aeruginosa. The in vitro properties of the isolated phages support their further evaluation as candidate antibacterial agents against resistant P. aeruginosa. However, genomic characterization, phage-antibiotic interaction analyses, and in vivo investigations are required before their broader applicability can be determined.
2. Litwin A, Rojek S, Gozdzik W, Duszynska W. Pseudomonas aeruginosa device associated–healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study. BMC Infect Dis 2021; 21: 180.
3. Zakhour J, Sharara SL, Hindy JR, Haddad SF, Kanj SS. Antimicrobial treatment of Pseudomonas aeruginosa severe sepsis. Antibiotics (Basel) 2022; 11: 1432.
4. Sawant S, Shaikh S, Baldwin TC, Karakoula A, Rahman A. Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies. Arch Microbiol 2026; 208: 351.
5. Shariati A, Azimi T, Ardebili A, Chirani A, Bahramian A, Pormohammad A, et al. Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes New Infect 2017; 21: 75-80.
6. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32(4): e00031-19.
7. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2014; 3: 32.
8. Ramatla T, Nkhebenyane J, Lekota KE, Thekisoe O, Monyama M, Achilonu CC, et al. Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis. Front Microbiol 2025;16:1599070.
9. Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol 2012; 12: 156.
10. Soothill J. Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections. Exp Rev Anti Infect Ther 2013; 11: 909-915.
11. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017; 8: 162-173.
12. Alharbi NM, Ziadi MM. Wastewater as a fertility source for novel bacteriophages against multi-drug resistant bacteria. Saudi J Biol Sci 2021; 28: 4358-4364.
13. Iwańska A, Trafny EA, Czopowicz M, Augustynowicz-Kopeć E. Phenotypic and genotypic characteristics of Pseudomonas aeruginosa isolated from cystic fibrosis patients with chronic infections. Sci Rep 2023; 13: 11741.
14. Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st Edition. J Clin Microbiol 2021; 59(12): e0021321.
15. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol 2009; 501: 69-76.
16. Marashi SMA, Nikkhahi F, Hamedi D, Shahbazi G. Isolation, characterization and in vitro evaluation of specific bacteriophages targeting extensive drug resistance strains of Pseudomonas aeruginosa isolated from septic burn wounds. Infect Chemother 2022; 54: 153-164.
17. Khan Mirzaei M, Nilsson AS. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One 2015; 10(3): e0118557.
18. Fang Q, Zong Z. Lytic phages against ST11 K47 carbapenem-resistant Klebsiella pneumoniae and the corresponding phage resistance mechanisms. mSphere 2022; 7(2): e0008022.
19. Ahmed SK, Hussein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, et al. Antimicrobial resistance: Impacts, challenges, and future prospects. J Med Surg Public Health 2024; 2: 100081.
20. Yan B, Yan C, Ding Y, Cai S, Wang Y, Agbo E, et al. Multidrug-resistant Pseudomonas aeruginosa infections: current status, challenges, and prospects of phage therapy. Front Microbiol 2026; 16: 1723885.
21. Pal N, Sharma P, Kumawat M, Singh S, Verma V, Tiwari RR, et al. Phage therapy: An alternative treatment modality for MDR bacterial infections. Infect Dis (Lond) 2024; 56: 785-817.
22. Aranaga C, Pantoja LD, Martínez EA, Falco A. Phage therapy in the era of multidrug resistance in bacteria: a systematic review. Int J Mol Sci 2022; 23: 4577.
23. Sadeqi S, Shahraki AH, Nikkhahi F, Javadi A, Marashi SMA. Application of bacteriophage cocktails for reducing the bacterial load of nosocomial pathogens in hospital wastewater. Iran J Microbiol 2022; 14: 395-401.
24. Shokri D, Soleimani-Delfan A, Fatemi SM. Assessment of phage cocktails with extended host range activity against antibiotic resistant strains of Pseudomonas aeruginosa. Comparative Clin Pathol 2017; 26: 417-422.
25. Barazandeh M, Shahin K, Hedayatkhah A, Komijani M, Mansoorianfar M. Characterization of a novel bullet-shaped lytic bacteriophage against extensively drug-resistant Pseudomonas aeruginosa isolated from human and domestic sources. Vet Res Forum 2021; 12: 401-407.
26. Elfadadny A, Ragab RF, Abd Alaziz OA, Essa HY, Eltony EM, Ammar MM, et al. Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections. J Chemother 2025: 1-12. doi: 10.1080/1120009X.2025.2547147.
27. Zerbini FM, Crane A, Kuhn JH, Simmonds P, Lefkowitz EJ, Consortium ITS, et al. Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses (ICTV)–General taxonomy proposals, 2025. J Gen Virol 2025; 106: 002116.
28. Kurt KC, Kurt H, Tokuç E, Özbey D, Arabacı DN, Aydın S, et al. Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Sci Rep 2025; 15: 6551.
29. Wintachai P, Naknaen A, Thammaphet J, Pomwised R, Phaonakrop N, Roytrakul S, et al. Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo. Sci Rep 2020; 10: 11803.
30. Broncano-Lavado A, Santamaría-Corral G, Esteban J, García-Quintanilla M. Advances in bacteriophage therapy against relevant multidrug-resistant pathogens. Antibiotics (Basel) 2021; 10: 672.
31. El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis 2019; 69: 167-178.
32. Carroll-Portillo A, Coffman CN, Varga MG, Alcock J, Singh SB, Lin HC. Standard bacteriophage purification procedures cause loss in numbers and activity. Viruses 2021; 13: 328.
| Files | ||
| Issue | Vol 18 No 4 (2026) | |
| Section | Original Article(s) | |
| Keywords | ||
| Bacteriophages Pseudomonas aeruginosa Antibiotic resistance | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
